Novel small synthetic HIV-1 V3 crown variants: CCR5 targeting ligands

Received 3 January 2022; accepted 2 June 2022; published online 16 June 2022

Anju Krishnan Anitha1,2, Pratibha Narayanan1,2, Neethu Ajayakumar1,2, Krishnankutty Chandrika Sivakumar1 and Kesavakurup Santhosh Kumar1,†

1Chemical Biology Laboratory, Pathogen Biology Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India; and 2University of Kerala, Thiruvananthapuram, Kerala, 695014, India

†Kesavakurup Santhosh Kumar, Chemical Biology Laboratory, Pathogen Biology Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India. Tel.: +91471 2529518, email: kskumar@rgcb.res.in

The CC chemokine receptor 5 (CCR5) antagonism represents a promising pharmacological strategy for therapeutic intervention as it plays a significant role in reducing the severity and progression of a wide range of pathological conditions. Here we designed and generated peptide ligands targeting the chemokine receptor, CCR5, that were derived from the critical interaction sites of the V3 crown domain of envelope protein glycoprotein gp120 (TRKSIHIGPGRAFYTTGEI) of HIV-1 using computational biology approach and the peptide sequence corresponding to this region was taken as the template peptide, designated as TMP-1. The peptide variants were synthesized by employing Fmoc chemistry using polymer support and were labelled with rhodamine B to study their interaction with the CCR5 receptor expressed on various cells. TMP-1 and TMP-2 were selected as the high-affinity ligands from in vitro receptor-binding assays. Specific receptor-binding experiments in activated peripheral blood mononuclear cells and HOS.CCR5 cells indicated that TMP-1 and TMP-2 had significant CCR5 specificity. Further, the functional analysis of TMP peptides using chemotactic migration assay showed that both peptides did not mediate the migration of responsive cells. Thus, template TMP-1 and TMP-2 represent promising CCR5 targeting peptide candidates.

Keywords: V3 crown; RANTES; gp120; CCR5 antagonism; CCR5.

Introduction

CC chemokine receptor 5 (CCR5), which is a member of the β chemokine receptor family, is mainly expressed on various immune cells, neurons, astrocytes, microglia, vascular smooth muscle and fibroblasts (1, 2). It is a key player in mediating the migration of cells during the immune response. On the contrary, it acts as a doorway for the development of various pathological conditions, including autoimmune diseases, allergic diseases, cancers and bacterial infections as well as in several viral infections caused by HIV-1, Zika virus, Epstein Barr virus, Rhinovirus, Rocio virus and Hepatitis B virus (3–7).

Graphical Abstract
CCR5 blockade represents a potential therapeutic approach to combat CCR5-related diseases. It is achieved either by employing gene-editing strategies to disable the cell surface expression of CCR5 or by CCR5 antagonism using various molecular entities. It was reported as an effective strategy to treat several cognitive defects, multiple sclerosis, neuroinflammation, and various cancers including breast cancer, ovarian cancer, prostate cancer, colorectal cancer, melanoma, multiple myeloma, and gastric cancer (8–13). CCR5Δ32 mutation, which prevents the cell surface expression of CCR5, was reported to provide resistance against HIV-1 infection, rheumatoid arthritis, and coronary artery disease (14–16). Reports suggest that CCR5 antagonism is effective against Crimean-Congo hemorrhagic fever, vaccinia virus infection, HIV infection, and Staphylococcus aureus pathogenesis (17–20). CCR5 targeting gained momentum again during the COVID-19 pandemic situation, with the identification of its involvement in the clinical progression of SARS-CoV-2 infection. CCR5 antagonism has also been reported as a potential treatment modality to combat corona infection, as CCR5 antagonists were found to be effective in treating the immune dysregulation caused by SARS-CoV-2 infection leading to the cytokine storm (21–23). The involvement of CCR5 in the development of various bacterial, parasitic, fungal, and viral infections and the associated immune dysregulation accelerated the efforts to develop CCR5 inhibitors as anti-infectives.

CCR5 targeting molecular entities mainly come under four categories: chemokine analogues, small molecule inhibitors, peptide-based inhibitors and monoclonal antibody. Chemokine analogues represent the first generation of CCR5 antagonists, as the endogenous chemokines serve as an excellent template for the generation of chemokine-based CCR5 antagonists. RANTES (regulated upon activation, normal T cell expressed and presumably secreted) is the extensively modified endogenous chemokine for developing chemokine analogues targeting CCR5 and few RANTES variants such as AOP-RANTES and PSC-RANTES, showed excellent HIV-1 inhibitory activity (24, 25). Peptide T is a peptide-based CCR5 antagonist derived from the V2 region of gp120. It binds competitively to the CCR5 and blocks the interaction between gp120/CD4 and CCR5 (26). Maraviroc, a small molecule CCR5 inhibitor developed by Pfizer, is the first Food and Drug Administration (FDA)-approved CCR5 antagonist for the treatment of naive and treatment-experienced HIV patients (27). In addition to this, the efficacy of maraviroc against several pathological conditions, including COVID-19, is being evaluated in clinical trials (28–32). Cenicriviroc is another small molecule CCR5 antagonist, which binds to a domain other than the extracellular loop 2 and the N terminus of CCR5 and induces a conformational change in the CCR5. It showed promising effects against HIV-1 infection, liver fibrosis, and fatty liver (33–35). It is also under clinical trials against HIV-1 and COVID-19 (36, 37). Lenorlimab (PRO-140) is a humanized monoclonal antibody that recognizes N-terminal and extracellular loop 2 of CCR5, which showed excellent effectiveness against HIV-1 infection, is currently retasked for triple-negative breast cancer, COVID-19, Graft-versus-host disease (37–41). There are a growing number of CCR5 antagonists in various phases of pre-clinical and clinical trials for the treatment of CCR5-related diseases (37).

As important as druggable target identification, the selection of a candidate molecule that can be used as the template to design CCR5 inhibitor is also critical in achieving effective receptor blockade. Since the CCR5 in complex with HIV-1 gp120 is well studied, the exploitation of such interaction interface holds great possibility to design potent CCR5 inhibitors. The crucial component of HIV-1 envelope protein involved in the initial interaction of both viral and host cell membrane is the envelope glycoprotein subunit: gp120. The gp120 subunit is composed of five relatively conserved (C1–C5) and five variable (V1–V5) domains (42, 43). The amino acid residues in the third variable region (V3) of gp120 shows a high degree of sequence diversity among various isolates and is one of the major immunogenic sites in the virus (56–58). Topologically, the V3 domain is divided into three distinct regions: the base, the stem, and the tip or crown.

In this study, we selected the V3 crown region and the few residues flanking on both sides of the V3 crown to generate CCR5 targeting ligands, as the residues in the crown region have been identified as the major determinants for coreceptor usage (39). The peptide derived from this region was termed TMP-1, and the possible interactions between the TMP-1 and CCR5 were exploited to generate high-affinity CCR5-binding ligands. The variants were designed by employing a systemic mutation approach, in which the certain amino acid residues of the TMP-1 were replaced with other residues based on the intermolecular interaction free energy of TMP-1:CCR5 complex and the available literature. The computationally derived complete structure of TMPs in complex with CCR5 receptor structure showed that the peptides interacted with CCR5 residues in the N-terminus, extracellular loop 1, 2 and 3 and transmembrane helices 1, 2, 3, 6 and 7. The in vitro receptor-binding experiments using rhodamine B-labelled TEMP-1 and variants conducted on CCR5 expressing cells showed that TEMP-1 and TEMP-2 displayed significantly higher binding ability than TEMP-3 and TEMP-4. The specificity of TEMP-1 and TEMP-2 towards CCR5 highlights their feasibility as efficacious CCR5 targeting candidate molecules.

Materials and Methods

Materials

RANTES Human Recombinant, Anti-Human CD195 (T21/8), Fluorescein Goat anti-mouse IgG(H+L), Ficoll-Paque Plus, Hoechst stain, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) dye, rhodamine B, CLEAR Resin, Rink amide linker and Fmoc protected amino acids, phyohaemagglutinin P (PHA-P).

Human osteosarcoma cells (HOS.CCR5) stably expressing CCR5 receptors were obtained from NIH AIDS Reagent Program, Division of AIDS, and were treated as per the protocol mentioned by the NIH AIDS Reagent Program for culturing and maintaining. The cells were cultured in DMEM and were supplemented with 10% heat-inactivated foetal bovine serum and 1% Penicillin.
Methods
Selection of template The V3 crown region of gp120, along with the flanking residues from both N and C-terminal region of the V3 stem was selected as the reference peptide for generating the CCR5 targeting ligands, as the CCR5 utilization of the gp120 envelope protein is primarily mediated by the residues in the V3 crown region of V3 loop (59, 61). The V3 loop is composed of approximately 35 residues, in which residues 1 and 35 are connected through a disulfide bridge. It possesses a net-positive charge, which can vary from +2 to +10 (47, 62).

Binding-free energy analysis of template peptide and designing of CCR5 targeting variants The primary sequence of the template was retrieved from the solution NMR structure of the V3 loop of the envelope protein gp120 from RCSB Protein Data Bank with PDB ID: 1CE4. The X-ray crystallography structure of the Maraviroc bound CCR5 was obtained from RCSB Protein Data Bank with PDB ID: 4MBS (63, 64). The alignment of V3 loop residues obtained from the PDB data is represented in the Fig. 1A. The binding-free energy and the critical interacting residues of the selected V3 crown region with the CCR5 receptor structure were analysed by molecular dynamics simulations using Gromacs 4.5.5 in a membrane-mimicking environment (65). The binding-free energy of the peptide residues was estimated using the g_mmpbsa module (66) by taking snapshots at every 10 ps from the 20 ns production run and the whole process was repeated until sufficient good scoring variants were received.

The residues in the template peptide with favourable binding energy and those reported as conserved were preserved. A systemic mutation approach was adopted to substitute residues with unfavourable binding energy with other amino acids in order to generate novel peptide variants. The variants were then modelled using Modeller 9.17. The modelled variants were then subjected to ZDock to predict their interaction with the receptor. ZDOCK uses a grid-based representation of two proteins and a 3-dimensional fast Fourier transform to explore the rigid-body search space of docking positions (67). The variants with better binding score than the TMP-1 were selected and were further subjected to molecular dynamics simulations using Gromacs 4.5.5 in a membrane-mimicking environment (65).

Chemical synthesis of CCR5 targeting peptide variants The peptide ligands were synthesized on Cross-Linked Ethoxylate Acrylate resins using Lyophil protected amino acids (Peptides International, Louisville, USA). On-resin fluorochrome (rhodamine B) labelling of peptides was also done. Following synthesis, the peptides were cleaved from the resin by treating with the cleavage cocktail comprising of TFA (95% v/v), thioanisole (2.5% v/v) and water (2.5% v/v) at room temperature for 3 hours with gentle intermittent stirring. The filtrate was collected, concentrated under vacuum, precipitated by ice-cold diethyl ether and recovered by centrifugation. The recovered peptide ligands were purified by RP-HPLC (Shimadzu) using Phenomenex Luna5u C18 analytical column (250 × 4.6 mm). Chromatographic separation was employed using a gradient mobile phase with a flow rate of 1 ml/min and the column temperature was kept up to 40°C. The detection was accomplished at 214, 510 and 540 nm. MALDI-TOF-MS analysis was performed using Bruker Daltonics Ultraflex MALDI TOF/TOF mass spectrometer to confirm the molecular mass of the peptide ligands.

Evaluation of CCR5 expression The expression of CCR5 on the HOS.CCR5, PBMC and THP-1 monocyte cell line was validated using anti CCR5 monoclonal antibody (T21/8) (eBioscience, Thermo Fisher Scientific, Waltham, Massachusetts, USA). Cells were resuspended in 1X PBS to a concentration of 5 × 10⁵ cells per reaction tube. The cells were blocked with 1% BSA in PBS and then incubated with 15 μg/ml anti-CCR5 monoclonal antibody for 3 hours at 4°C, followed by incubation with FITC-labelled secondary antibody (Invitrogen, Thermo Fisher Scientific, Waltham, Massachusetts, USA) for 1 hour in dark at 4°C. The fluorescence associated with the cells per sample was analysed using Flow cytometry (BD FACS Aria III).

Screening for the binding ability of TMP variants to CCR5 FACS-based ligand binding assay was done to determine the binding ability of variants. A single concentration of rhodamine-labelled variants (20 μM) was treated to the HOS.CCR5 cells and kept for 60 minutes at 4°C. Cells were then centrifuged at 2000 rpm for 3 minutes; the supernatant was then discarded and washed with 1X PBS twice. The cells were resuspended in DMEM medium, and the fluorescence was analysed by flow cytometry.

Evaluation of ligand binding by confocal microscopy HOS.CCR5 cells were cultured on a coverslip at a density of 1 × 10⁴ cells/well overnight. The media was removed and washed twice with 1X PBS before the treatment of samples. A single concentration (20 μM) of rhodamine-labelled variants was added to the coverslip and incubated for 60 minutes at 4°C. The unbound variants were washed using 1X PBS, then the samples were fixed in 4% formaldehyde and all samples were incubated with 10 μg/ml Hoechst to stain the nuclei of the cells. Finally, the coverslips were mounted and imaging was performed using confocal microscopy (Leica SP8 WLL).

Analysis of CCR5 binding affinity of variants TMP-1 and TMP-2 at different concentration were treated in cells expressing varying levels of CCR5 (HOS.CCR5, THP-1 and PBMCs) and incubated for 1 hour at 4°C. The cells were then
centrifuged at 1500 rpm for 3 minutes and unbound ligands were removed by washing three times with 1X PBS buffer and were resuspended in 500 μl DMEM for flow cytometry analysis.

Effect of TMP binding on CCR5 specific antibody binding The PBMCs cultured in the presence of PHA were harvested and centrifuged at 400 × g and treated with 20 μM of TMP-1 and TMP-2. The treated cells were incubated at 4°C for 1 hour and then washed three times with 1X PBS to remove unbound ligands. Following this, 15 μg/ml of monoclonal antibody (T21/8) against CCR5 was added and incubated at 4°C for 3 hours and, finally, the cells were incubated for 1 hour with a secondary antibody conjugated with FITC at dark. The control wells were treated with media alone. The cells that were treated only with antibody served as the comparative sample. The cells were then washed with PBS thrice to remove the unbound secondary antibody and the samples were analysed by flow cytometry.

Specific binding of TMP variants A competitive binding strategy was adopted to determine the specificity of variants using excess endogenous ligand of CCR5 receptor, RANTES (Sigma-Aldrich); 5 × 10⁵ HOS.CCR5 cells were treated with either excess RANTES and single concentration (20 μM) of rhodamine-labelled TMP variants or TMP variants alone. Following the incubation for 60 minutes at 4°C, the cells were washed thrice using 1X PBS to remove the unbound peptides. The cells treated with the variants alone served as the comparative control and the untreated cells served as the control.

Chemotactic migration assay Two strategies were adopted to examine the chemotactic activity of TMP variants towards HOS.CCR5 cells. Using Transwell chambers (Corning, New York, USA), the responsive cell migration towards the variants was quantified. The cells were treated with serum-free medium for 5 hours prior to the treatment of variants. Different concentration of the TMP variants (0.1, 1.0, 10, 100 μM) were added to the lower wells of the chamber, and cells in FBS-free medium were added to the upper chamber. The upper and lower chambers were separated by a filter of pore size of 8 μM. The whole chamber was incubated at 37°C for 4 hours. The filter was then removed and migrated cells were fixed and stained by crystal violet and counted in three microscopic fields. Two inserts were used for each treatment, in which the control group was treated with media alone and RANTES (10 nM)-treated cells served as the positive control.

Agarose spot assay was done to confirm the variant-mediated chemotaxis of responsive cells. A total of 0.5% agarose in PBS was heated on a hot plate and stirred till complete dissolution. After complete melting, it was cooled to 40°C. The variants at the concentration of 0.1, 1.0, 10, and 100 μM were prepared in 0.5% agarose in PBS. The spots of peptide-containing agarose (20 μl) were placed in each well and were allowed to solidify at 4°C for 5 minutes. The spots containing PBS alone and RANTES (10 nM) served as the control and positive control, respectively. A total of 5 × 10⁵ cells along with FBS free media were added to each well and incubated for 4 hours in a CO₂ incubator. The media along with cells were replaced with fresh media and imaging was performed.

CCR5 internalization assay The down-modulation of cell surface CCR5 was done as per previously published protocols. The activated PBMCs were seeded in six-well plates and incubated overnight at 37°C. The following day, the media was replaced with fresh FBS-free media and incubated for 3 hours prior to the experiment. The cells
were treated with different concentration of variants (0.1, 1.0, 10, 100 μM) and RANTES (10 nM) and incubated for 60 minutes at 37 °C, transferred to 4°C and kept for 5 minutes, and washed with ice-cold acid stripping buffer. The unbound CCR5 was then stained by anti-CCR5 monoclonal antibody for 3 hours at 4°C and then with the secondary antibody for 1 hour at dark. The cells treated with RANTES served as positive control. The fluorescence was quantified by flow cytometry analysis.

In vitro toxicity studies of variants The cytotoxic effect of variants against HOS.CCR5 cells and isolated PBMCs was evaluated by MTT assay (72). HOS.CCR5 cells (1 × 10^4) and PBMCs (1 × 10⁶) were seeded in each well of 96-well plates and kept overnight in DMEM medium containing 10% FBS. Cells were then incubated in the presence of various concentration of variants over 48 hours. Cells treated with 1% TritonX100 were used as the positive control. The cells were then treated with 100 μL of MTT solution (5 mg/ml) and incubated for 4 hours at 37°C. The insoluble formazan product was solubilized by the addition of DMSO to each well and the optical density was measured at 570 nm after 10 minutes using a microplate reader (Biorad).

Hemolytic activity of variants was determined by treating various concentration of peptides in suspensions of human RBC. A total of 5 ml of human blood was drawn directly into EDTA coated tubes. The blood was centrifuged at 800 × g for 10 minutes at 4°C; the levels of haematocrit and plasma were marked on the tube; and the plasma layer was aspirated. A total of 150 mM NaCl was added up to the mark and mixed by inversion. The whole content was then centrifuged at 500 × g and the supernatant was aspirated. 1X PBS was added up to the mark and spun at 500 × g for 5 minutes and washed twice using PBS. The optical density of the blood was adjusted to 1.2 at λ600 using 1X PBS. Red blood cells were then incubated at room temperature for 30–45 minutes in 1% Triton X-100 (positive control), in PBS (blank), and with TMP variants. The treated samples were centrifuged at 800 × g for 5 minutes, the supernatant was separated and the absorbance was measured at 540 nm. The percentage hemolysis of treated samples was analysed by determining the absorbance value compared to that of positive control.

Statistical Analysis Data are expressed as mean ± S.E. of two independent experiments. The statistical significance was performed by two-tailed unpaired Student’s t-test or one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. The analysis was done using GraphPad Prism 6 software. The statistically significant results are represented in the graph with stars (*, **).

Results

Selection of template and preparation of the receptor

The region between the N and C-terminal end located within 8–26 residues (TRKSIHIGPGRAYTGEI) of the V3 region (303–321 residues of gp120), comprising primarily of V3 crown of HIV-1 gp120 was selected as the template for designing peptide variants targeting CCR5 (Fig. 1A) (59). The template peptide is designated as TMP-1 throughout the study. The direct interaction of V3 crown-derived peptides to the CCR5 receptor was examined by in silico approach. The N-terminal region of CCR5, which is critical for HIV-1 gp120 binding, ligand binding and coreceptor functioning, was not solved in the crystal structure and was modelled using Modeller 9.17 (PDB ID: 4MBS) (73–75).

Intermolecular interaction free energy of TMP-1 in complex with CCR5

The interaction of 19-mer template peptide sequence ‘TRKSIHIGPGRAYTGEI’ (TMP-1) with CCR5 was performed using ZDock and molecular dynamics simulations. The preliminary docking of the TMP-1 with the CCR5 receptor structure (PDB ID: 4MBS) was done to obtain the TMP-1:CCR5 complex structure, which was further subjected for molecular dynamic simulation studies in a membrane-mimicking environment to obtain the free energy of binding. The intermolecular interaction free energy analysis of TMP-1 in complex with CCR5 validated the contribution of each residue in TMP-1 for their interaction with CCR5. The residues Thr1, Arg2, Lys3 (Thr303, Arg304, Lys305), Arg11, Gly17, Asp18 and Ile19 (Arg313, Gly319, Asp320, Ile321) showed higher interaction free energy (Fig. 1B). Residues Arg2, Lys3 and Arg11 have already been reported to be critical in CCR5 binding, and their replacement has been shown to reduce the CCR5 utilization and binding (76, 77). The conserved GPG motif -Gly8, Pro9 and Gly10 (Gly310–Pro311–Gly312) located in the V3 crown region did not show significant influence on binding affinity in terms of the binding score.

Designing and chemical synthesis of TMP variants

TMP variants were designed primarily based on the available literature and the obtained intermolecular interaction free energies of individual amino acid residues of TMP-1:CCR5 complex. The residues with the highest negative binding energy score and those residues that were reported to have a key role in CCR5 binding and specificity were retained in most of the variants. Thus, three variants (TMP-2, TMP-3, TMP-4) were generated and were subjected to ZDock and molecular dynamic simulation analysis in a membrane-mimicking environment (78). Interestingly, all the variants showed significantly higher dock score and binding energy scores than the TMP-1 (Table 1). Residues Arg2 and Lys3, which were already reported to be critical in CCR5 binding, were retained in all the variants. A conservative replacement strategy was adopted for the arginine residue at the 11th position (R11), which was experimentally shown as a key residue in CCR5 utilization (76, 77). The residue Arg11 of TMP-2 and TMP-3 was replaced by Lys11 (R11K). The more conserved GPG motif -Gly8, Pro9 and Gly10 (Gly310–Pro311–Gly312) located in the V3 crown region, which was reported to have a significant role in offering the conformational flexibility to the V3 loop, was also retained in all the variants (79–81). All the designed variants were found to be interacting with the same region of the CCR5 (Fig. 2; Supplementary Fig. 1). The computationally derived complete structure of TMPs in complex with CCR5 receptor structure showed that the peptides...
Table 1. Total binding energy values of the TMP-1 and variants obtained by ZDock and molecular dynamic simulation

| Variants | Sequence         | ZDock score (cal/mol) | Binding score (kJ/mol) |
|----------|------------------|-----------------------|------------------------|
| TMP-1    | TRKSIHGGRAFYTTYEI| −1435.4               | −509.8                 |
| TMP-2    | TRKRIHLGPKAFYTTYGDV| −441801.4            | −657.2                 |
| TMP-3    | TRKSIHGPGKAFYTTYDI| −406940.8            | −540.69                |
| TMP-4    | TRKSVHGPGRAFYTTYGEA| −94372.3            | −530.9                 |

Fig. 2. Interaction of TMP with CCR5. The structure of (A) CCR5:TMP-1, (B) CCR5:TMP-2, (C) CCR5:TMP-3 and (D) CCR5:TMP-4 generated by molecular dynamic simulation. The CCR5 receptor structure is represented in green, and the TMP variants are represented in yellow, pink, purple and blue.

interacted with CCR5 residues in the N-terminal region, extracellular loop (ECL1), ECL2, ECL3, transmembrane helical region 1 (TM 1), TM 2, TM 3, TM 6 and TM 7, through van der Waals, π–π and hydrogen bond interactions. The residues in the TMP-1 were predominantly involved in the interaction with the residues in N-terminal region, ECL2 and TM 2 of CCR5. The residues in the TMP-2 were found to predominantly interacting with the CCR5 residues in N-terminal region, ECL1, ECL2 and TM 2, whereas TMP-4 residues were mainly interacting with CCR5 N-terminal, ECL1 and TM7 and, finally, the residues in the TMP-3 were primarily involved with residues in the ECL2, TM6 and TM 7 (Supplementary Tables I–IV).

The unlabelled and rhodamine B-labelled TMP-1 and variants were chemically synthesized by Fmoc-solid phase peptide synthesis. The unlabelled peptide variants were purified by RP-HPLC under the detection wavelength of 214 nm. It is evident from the chromatogram of the variants that the retention time of all the variants followed a similar pattern, which could be due to the sequence homology of the variants. The labelled TMP variants were also purified with the detection wavelength of 510 and 540 nm. The molecular weight of both the unlabelled and labelled variants was confirmed by MALDI-TOF-mass spectroscopy (Supplementary Table. V; Supplementary Fig. 2-9).

Evaluation of CCR5 expression

HOS.CCR5 cells, THP-1 monocyte cells and human PBMCs were evaluated for the CCR5 cell surface expression using T21/8 monoclonal antibody, mapped to the N-terminal domain of CCR5. It has already been reported that CCR5 expression in PBMCs is more in the case of HIV-1-infected individuals compared with that of normal individuals (82). The majority of the CCR5 in the PBMCs are expressed mainly by the monocyte component (~80%), whereas the lymphocyte component expresses ~50% CCR5 (83). The percentage of CCR5 expression in PBMC was obtained as 75 ± 2.4%. The monocytes predominantly express CCR5, and it was reported that the THP-1 monocytes after Phorbol myristate acetate (PMA) treatment express ~96.9% CCR5 (84). Our immunostaining results also showed a similar pattern of CCR5 expression in THP-1 cells. The staining of anti-CCR5 antibody with THP-1 monocyte cells after 72 hours of PMA treatment showed 95 ± 0.3% FITC positive cells. HOS.CCR5 cells showed 99 ± 5% FITC positive cells (Supplementary Fig. 10A, B).

Binding ability of TMP variants

The CCR5-binding ability of TMP-1 and the designed variants was evaluated by flow cytometry analysis. The
CCR5 targeting peptide ligands

Fig. 3. The binding ability of rhodamine-labelled TMP variants with CCR5 analysed using flow cytometry and confocal microscopy. (A) The histogram showing the rhodamine-positive cells in control: TMP-1, TMP-2, TMP-3, TMP-4. TMP-1 and TMP-2 showed significant binding with CCR5, whereas the cell population treated with TMP-3 and TMP-4 did not show binding activity. The quantitative overview of binding of (B) TMP-1 and (C) TMP-2 with CCR5 expressing cells. The binding of varying concentration of TMP variants to HOS.CCR5, THP-1 and PBMCs in terms of percent rhodamine B-positive population was obtained by flow cytometry analysis. TMP-1 and TMP-2 showed a concentration-dependent binding in all three cells. Data are expressed as mean ± S.D. of two independent experiments. (D) Confocal microscopy images of TMP variants treated HOS.CCR5 cells with nuclei stained with Hoechst and rhodamine B-tagged TMP-1, TMP-2, TMP-3 and TMP-4 were observed. HOS.CCR5 cells were treated with single concentration (20 μM) of rhodamine-labelled peptides (TMP-1, TMP-2, TMP-3, TMP-4) and incubated for 60 minutes at 4°C. The cells that were not treated with peptides were taken as control. The cells treated with TMP-1 and TMP-2 showed significant rhodamine B fluorescence compared with that of cells treated with TMP-3 and TMP-4 (Fig. 3A). The binding ability in the terms of rhodamine-positive cells showed that the peptide derived from the V3 region of gp120 (TMP-1) had the highest binding activity among the variants followed by TMP-2, TMP-3 and TMP-4. Confocal microscopic studies of rhodamine B-labelled peptides binding to CCR5 confirmed the flow cytometry-based binding data, where TMP-1 and TMP-2 showed significant binding to the CCR5 transfected HOS.CCR5 cells (Fig. 3D). Thus, TMP-1 and TMP-2 were selected for further in vitro receptor binding studies.

The binding ability of the TMP-1 and TMP-2 was further validated in cells expressing varying levels of CCR5 (HOS.CCR5, PBMCs, THP-1) at different concentration. The cell population treated with various concentration of TMP-1 and TMP-2 showed a concentration-dependent binding in all three cell lines (Fig. 3B, C). The peptides showed the highest binding activity towards both THP-1 and HOS.CCR5 followed by PBMCs. This is in consistent with the immunostaining result, in which the expression level of CCR5 in PBMCs was low in comparison with the HOS.CCR5 and THP-1.

Inhibitory effect of TMP binding on CCR5 specific antibody binding

The specificity of TMP peptides was evaluated by pre-treating TMP-1 and TMP-2 with activated PBMCs, followed by incubating the cells with anti-CCR5 monoclonal antibody. The pre-incubation of TMP-1 and TMP-2 with PBMCs inhibited the binding of T21/8 to CCR5 (Fig. 4). The cell population treated with TMP-1 and TMP-2 showed a significant reduction in the FITC fluorescence compared with that of cells treated with monoclonal antibody alone. The pre-treatment of TMP-1 reduced the FITC fluorescence up to 30%, whereas TMP-2 showed a 39% reduction in the FITC positive population. The reduction in the FITC fluorescence was more in cells treated with TMP-2, which suggests that TMP-2 is more specific to CCR5. The specific binding of variants to the cells harbouring the similar family of receptors confirmed the targetability of both TMP-1 and TMP-2.

Specific binding of variants

A competitive binding strategy was carried out to determine the specificity of TMP-1 and TMP-2 to CCR5 receptor, in which the cells were treated with rhodamine B-labelled peptides with or without excess RANTES. The percentage fluorescence associated with cells treated in the presence and absence of excess RANTES was examined using flow cytometry. The cells that were treated with both peptides and excess RANTES showed a notable reduction in the fluorescence compared with cells treated with variants alone. The reduction in fluorescence up to 20% was observed on the treatment with excess RANTES along with TMP-1. Similarly, the cells treated with TMP-2 along with RANTES showed a reduction in the fluorescence up to 34% (Fig. 5). The reduction in the binding of TMP-1 and TMP-2 to the CCR5 in the presence of excess RANTES confirmed that TMP-1 and TMP-2 were specifically targeting CCR5.
Chemotactic migration assay
Chemokines are chemoattractant cytokines, involved in leukocyte activation and their migration. The responsiveness of CCR5 to the TMP-1 and TMP-2 was validated by measuring the chemotactic activity using transwell migration assay. Chemotaxis experiments were performed on HOS.CCR5 cells. TMP-1 and TMP-2 in the concentration range of 0.1–100 μM were used. Specific agonist RANTES served as the positive control and cells treated with PBS served as the control. TMP-1 consistently appeared to be non-chemotactic at all the concentration tested, whereas TMP-2 at 100 μM showed mild chemotactic response towards the CCR5 expressing cells. The migration of cells in response to RANTES was observed (Fig. 6).

The chemotaxis was further confirmed using agarose spot assay using HOS.CCR5 cells. A total of 0.5% agarose in PBS (negative control), RANTES (positive control) and TMP variants at different concentration were spotted in each well. Inconsistent with the quantitative transwell migration assay, cell migration was not observed under the agarose spot containing TMP-1. However, cell migration was observed under the spot containing TMP-2 at 100 μM. The cells did not migrate under the agarose spot without a chemoattractant and was taken as the control and cell migration was observed in response to spots containing 10 nM RANTES (Supplementary Fig. 11).

CCR5 internalization assay
Activated PBMCs were used to investigate the CCR5 internalization mediated by TMP peptides. The cells were incubated with serum-free medium for 2 hours, followed by the treatment of peptides at the different concentration for 1 hour at 37°C to evaluate the internalization rate. The cells were then transferred to 4°C and the surface-bound variants were removed using acid stripping buffer, followed by PBS washes. The cell surface CCR5 was stained using T21/8 and secondary antibody. The TMP-2 induced 30% receptor internalization at a concentration of 10 μM, whereas TMP-1 at concentration ranging from 0.1 to 100 μM failed to mediate CCR5 internalization in PBMCs (Fig. 7).
Fig. 6. Chemotactic response of TMP variants at various concentration towards HOS.CCR5 cells was measured by transwell migration assay. The chemotactic response of the HOS.CCR5 cells in the presence of TMP-1, TMP-2, RANTES (positive control) and PBS alone (control) was evaluated. TMP variants at different concentration (0.1, 0.1, 10, 100 μM) and RANTES (10 nM) were added to the lower wells of the chamber and the HOS.CCR5 cells in FBS-free DMEM were added to the upper chamber and was incubated at 37°C for 4 hours. The filter was then removed and migrated cells were fixed and stained by crystal violet and counted. Data are presented as the mean number of cells counted in each field ± SD of two independent experiments. One-way ANOVA followed by Dunnett’s multiple comparison test was performed and the asterisk (*) represents statistical significance in comparison with the control (P < 0.05).

Fig. 7. Internalization of CCR5 in PBMCs. Dose-dependent effect on CCR5 internalization in PBMCs treated with TMP-2 was observed, whereas TMP-1 did not show any effect on CCR5 internalization. The results are presented as the mean ± SD of two independent experiments on the same buffy coat. One-way ANOVA followed by Dunnett’s multiple comparison test was performed, and the asterisk (**) represents statistical significance in comparison with the control (RANTES) (**P < 0.01).

displayed a similar level (40–50%) of toxicity against both the target cells (Fig. 8a, b).

The cytotoxicity of TMP variants towards human RBCs was also evaluated. At the highest concentration, the TMP-1 and TMP-2 showed only 13% and 20% of hemolysis, respectively (Fig. 8c).

Discussion

The CCR5 chemokine receptor is involved in immune and inflammatory responses, as well as in the progression of various human diseases (7). The recent outbreak of COVID-19 put the world on hold and made the situation miserable due to the lack of appropriate therapeutic approaches. Subsequent studies have identified the involvement of several other receptors, including CCR5 in COVID-19-related disease severity (85). The role of CCR5 in HIV-1 pathogenesis is well studied. Aside from its role in facilitating HIV-1 entry, CCR5 is involved in the formation of latent reservoirs, as majority of the viruses in the latent reservoir use CCR5 (86). In 2009, a case report showed that a Berlin patient, who had received the allogenic stem cells from a homozygous CCR5 donor, achieved functional cure of HIV-1 infection, along with the reduction in the size of the viral reservoir (87, 88). The comprehensive analysis of his viral reservoir revealed that the HIV DNA levels were 7500-fold lower than those in patients receiving typical antiretroviral therapy (ART) (89). The involvement of CCR5 in the formation of drug resistant latent HIV-1 reservoir indicates the significance of targeting CCR5 beyond the perspective of entry inhibition. A rare group of individuals referred to as long-term nonprogressors, who have been able to maintain CD4+ T cell count and control the HIV-1 replication even in the absence of antiretroviral therapy, represent a model for functional cure (90). Several studies showed that the host factors and effective immunologic response plays crucial role in controlling the infection (91, 92). A recent study has shown that HIV-specific CD4+ T cells of controllers express low levels of CCR5, which inhibits the entry of HIV-1 (93). Thus, the CCR5 represents a target with multifaceted effects in the case of HIV-1 pathogenesis and disease progression. Studies using nonhuman primate as models for SIV infection showed that circulating CCR5+ memory CD4+ T cells from blood, mesenteric lymph nodes, mucosal surfaces such as gut, were selectively depleted in rapidly progressing SIV-infected monkeys during the initial phase of infection (99–101). These findings emphasized the importance of developing regimens that can achieve maximum virologic suppression during the early phase of infection. The combination of ART with CCR5 inhibitors may serve as an effective strategy to achieve cure, to prevent disease progression and to compensate for the shortcomings of existing therapy. Maraviroc is the only CCR5 inhibitor used in the treatment of naive and treatment-experienced HIV patients. Maraviroc-containing regimen achieved high rates of viral suppression and immunological responses in individuals who had failed to respond to previous regimens (94). Recent studies have shown that maraviroc can reactivate latent HIV in vivo (95). DAPTA is a short peptide derived from the V2 region of HIV gp120, which selectively targets CCR5. Monomeric DAPTA is 1000-fold more potent than maraviroc in inhibiting HIV-1 entry. The combination of ART along with DAPTA brought about an effective suppression of active HIV replication in the blood monocytes compared with peptide alone or by ART alone in individuals with stable plasma viremia (96–98).

The efforts to achieve CCR5 antagonism led to the development of various CCR5 targeting molecular entities, including chemokine analogues, small CCR5 molecule inhibitors and anti-CCR5 monoclonal antibodies (7). The peptide-based CCR5 inhibitors gained significant momentum, as peptide-based anti-viral therapeutics require evolutionary mutations or drastic changes in the viral structures for the virus to develop resistance against peptides (102). Unlike small molecule inhibitors, peptides can target protein–protein interactions more effectively because of their affinity for large protein surfaces (103). Chemokine variants represent the first generation of peptide-based CCR5 inhibitors and have been used in the treatment of naive and treatment-experienced HIV patients. Maraviroc-containing regimen achieved high rates of viral suppression and immunological responses in individuals who had failed to respond to previous regimens (94). Recent studies have shown that maraviroc can reactivate latent HIV in vivo (95). DAPTA is a short peptide derived from the V2 region of HIV gp120, which selectively targets CCR5. Monomeric DAPTA is 1000-fold more potent than maraviroc in inhibiting HIV-1 entry. The combination of ART along with DAPTA brought about an effective suppression of active HIV replication in the blood monocytes compared with peptide alone or by ART alone in individuals with stable plasma viremia (96–98).

The involvement of CCR5 in various human diseases, including neurodegenerative conditions, has led to the development of CCR5 antagonists as potential therapeutic agents. The recent advances in the field of CCR5-based therapies have opened up new avenues for the treatment of various diseases, including HIV and neurodegenerative conditions. However, the efficacy and safety of CCR5 inhibitors remain to be fully elucidated. Further studies are needed to better understand the role of CCR5 in disease progression and to develop more effective therapeutic strategies.
inhibitors. The variants showed greater receptor specificity and selectivity than endogenous chemokine ligands. Few among the chemokine variants showed better anti-HIV-1 activity than that of maraviroc, and it has been reported that 5P12-RANTES resists the development of HIV-1-resistant strains (104, 105). Despite this, the clinical development of synthetic chemokine variants is difficult due to their high molecular weight, CCR5 agonist activity and their high cost of production. The generation of short peptides targeting CCR5 would be highly promising in this regard.

The idea for designing the peptide variants in this study came after paying close attention to the well-characterized HIV-1 gp120:CCR5 complex (106). A series of experiments depicted that certain residues or regions in the gp120 are involved in the host receptor binding and pathogenesis (77, 79, 80, 107, 108). Such an interaction interface could provide potential opportunity to develop inhibitors targeting the CCR5 receptor. This wealth of information provided the basis for selecting the primary sequence of peptide derived from the V3 crown region as the template (TMP-1) to generate the variants targeting CCR5. The validation of this approach has been obtained from a study conducted by Sakaida et al. (109). They showed that the peptides derived from the V3 loop of naïve CD4-tropic HIV-1 interacted with its coreceptor CXCR4, independently of other variable regions or primary receptor CD4 (109). Molecular dynamic simulation was employed to design the TMP variants, as it is a widely used approach in studying ligand-receptor interaction and template-based drug designing (110). The key residues involved in TMP-1:CCR5 interaction were identified, and the binding energy of TMP-1 in complex with the receptor structure was obtained by molecular dynamic simulations. The TMP-2, TMP-3 and TMP-4 were designed based on the intermolecular interaction scores of individual amino acid residues of TMP-1 in complex with CCR5 receptor.

Several studies have indicated that the N-terminus, ECL2 and transmembrane helical regions 1, 2, 3 and 7 of CCR5 were critically involved in interacting with several small molecule CCR5 inhibitors, chemokine ligands and HIV-1 gp120 (75, 111–115). Consistent with this, the computationally derived complete structure of TMPs in complex with CCR5 showed that all the TMPs interacted with the aforementioned regions in the CCR5 receptor. Our analysis also showed that certain residues of CCR5 receptor such as Tyr14, Tyr15, Glu18, Pro19, Lys26, Leu33, Tyr37, Trp86, Tyr89, Ala90, Trp94, Leu104, Tyr108, Phe109, Gln170, Thr177, Cys178, Ser179, Ser180, His181, Phe182, Tyr184, Tyr187, Lys191, Ile198, Tyr251, Leu255, Asn258, Asp276, Met279, Gln280, Glu283 and Met287 were involved in TMP:CCR5 interaction. These residues have already been experimentally or computationally shown to interact with several small molecule CCR5 inhibitors, chemokine ligands and HIV-1 gp120 (106, 116–119). Such common residues in CCR5 that are being shared between a wide range of ligands represent key residues or regions to be targeted for developing CCR5 receptor antagonists or inhibitors.

The peptide variants were chemically synthesized using solid-phase peptide synthesis and were further labelled with rhodamine B to probe their in vitro binding ability. Synthetic peptides targeting CCR5 have been generated and shown to exhibit effective CCR5 blockade (120). The CCR5 targeting ability of the TMPs was examined in cell lines expressing varying levels of CCR5 receptor, as our goal was to generate variants with high receptor selectivity. Our in vitro findings demonstrated that the rhodamine
B-labelled TMP-1 and TMP-2 had higher binding ability as compared with TMP-3 and TMP-4. The promiscuous nature of the chemokine system often complicates the development of CCR5 specific ligands. The ability of the peptides to specifically target CCR5 was examined in PBMCs, which express various other chemokine receptors (83). The ability of the TMP-1 and TMP-2 to inhibit the binding of CCR5-specific monoclonal antibody in PBMCs, which harbour the pool of similar chemokine receptors, showed their effectiveness in targeting CCR5. The specificity of TMP-1 and TMP-2 was further confirmed using competitive binding experiment in the presence of excess RANTES.

In normal physiological conditions the binding of respective ligands to the CCR5 receptor leads to a rapid response such as receptor phosphorylation leading to calcium mobilization, chemotaxis and also the delayed response such as CCR5 internalization (121). The surface expression of CCR5 largely influences the ability of CCR5 in mediating disease development. In addition to the high-affinity receptor occupancy, CCR5 downmodulation was also suggested as an effective way to disable the cell surface distribution of CCR5. The PSC-RANTES, a variant generated from RANTES, which could mediate long-term internalization of CCR5, was reported to have potent anti-HIV-1 activity than other RANTES variants (122). Our, flow cytometry-based analyses showed that TMP-2-induced CCR5 receptor internalization, whereas TMP-1, with concentration ranging from 0.1 to 100 μM, failed to mediate CCR5 internalization. The hallmark of the chemokine system is its ability to induce chemotaxis of target cells, and this aspect assumes great significance while targeting the chemokine system for therapeutic intervention (123). In this regard we performed chemotactic migration assay in responsive cells, and the data confirmed that TMPs were not chemotactic in nature.

In conclusion, the peptides used in this study have shown promising CCR5 inhibitory activity, in which the template TMP-1 showed high affinity towards CCR5 receptor, whereas TMP-2 showed CCR5 inhibition either by masking the exposed CCR5 or by inducing internalization of CCR5 receptor, without significant G protein-linked signalling activity. Further studies are needed to validate the effect of these peptides against those pathogens that hijack CCR5 for pathogenesis.

Conclusion

Beyond the perspective of exploiting CCR5 as a target for inhibiting HIV-1 entry, being a highly redundant receptor having both positive and negative roles in the regulation of various physiological and pathological processes, CCR5 targeting represents a potential therapeutic strategy to combat several other infectious and non-infectious diseases. The significance of CCR5 targeting gained momentum again during the time of global COVID-19 pandemic, as the observation that CCR5 antagonism/blockade can be a potential therapeutic alternative to combat COVID infection, and the clinical trial of CCR5 antagonist cenicriviroc against COVID infection are underway (21, 22, 124). The study provided a preliminary hint regarding the efficacy of TMP variants in specifically targeting CCR5.

Data availability statement

All the data presented in the manuscript is provided in the main text and the supplementary file.

Supplementary Data

Supplementary Data are available at JB Online.

Acknowledgements

We thank Dr. T. R. Santhosh Kumar and his team for their assistance in handling different cell lines. We thank Dr. Ajay Kumar for providing THP-1 cell line. We thank Dr. Sarah Jones, Dr. John Bernet Johnson and Dr. Deepak Chouhan, for critical advise and valuable suggestions. We thank Mr. Johney Philip, Ms. Smita Devi and Mr. Manu N M for helping in setting up instruments and experiments in the lab. We also thank RGCB instrument facilities specially MALDI-MS facility, flowcytometry, microscopy (confocal microscope) and Mr. Tilak Prashad, Ms. Surabhi and Mr. Anuroop for technical assistance.

Funding

This work was supported by the Department of Biotechnology [grant number no. BT/PR8835/NDB/52/61/20072]. Anju Krishnan Anitha received financial support from the Kerala State Council for Science Technology and Environment.

Conflicts of Interest

The authors declare no conflict of interest.

Author Contributions

Conceptualization, K.S.K and A.K.A.; methodology, A.K.A.; software, K.C.S.; validation, K.S.K., A.K.A., P.N. and N.A.; formal analysis, K.S.K and A.K.A.; investigation, K.S.K.; resources, K.S.K.; data curation, K.S.K and A.K.A.; writing (original draft preparation), A.K.A.; writing (review and editing), K.S.K and A.K.A.; visualization, K.S.K.; supervision, K.S.K.; funding acquisition, K.S.K. All authors have read and agreed to the published version of the manuscript.

REFERENCES

1. Corbeau, P., and Reynes, J. (2009) CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS 23, 1931–1943
2. Rottman, J.B., Ganley, K.P., Williams, K., Wu, L., Mackay, C.R., and Ringler, D.J. (1997) Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am. J. Pathol. 151, 1341–1351
3. Chávez, J.H., França, R.F., Oliveira, C.J., de Aquino, M.T., Farias, K.J., Machado, P.R., de Oliveira, T.F., Yokosawa, J., Soares, E.G., and da Silva, J.S. (2013) Influence of the CCR-5/MIP-1α axis in the pathogenesis of Rocío virus encephalitis in a mouse model. Am. J. Trop. Med. Hyg. 89, 1013–1018

Supplementary Data
4. Badolato-Corrêa, J., Sánchez-Arcila, J.C., Alves de Souza, T.M., Santos Barbosa, L., Conrado Guerra Nunes, P., da Rocha Queiroz Lima, M., Gandini, M., Bispo de Filippis, A.M., Venâncio da Cunha, R., Leal de Azereido, E., and de-Oliveira-Pinto, L.M. (2018) Human T cell responses to dengue and Zika virus infection compared to dengue/Zika coinfection. *Immun. Inflamm. Dis.* **6**, 194–206

5. Zachova, K., Koszytu, P., Zadrzil, J., Matousovic, K., Vondrak, K., Hubacek, P., Kostovcikova, K., Hogenova, H.T., Mestecky, J., and Raska, M. (2020) Multiparametric flow cytometry analysis of peripheral blood B cell trafficking differences among Epstein–Barr virus infected and uninfected subpopulations. *Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub.* **164**, 247–254

6. Rajan, D., McCracken, C.E., Kopleman, H.B., Kyu, S.Y., Lee, F.E.-H., Lu, X., and Anderson, L.J. (2014) Human rhinovirus induced cytokine/chemokine responses in human airway epithelial and immune cells. *PLoS One* **9**, e114322

7. Vangelista, L., and Vento, S. (2018) The expanding therapeutic perspective of CCR5 blockade. *Front. Immunol.* **8**, 1981

8. Necula, D., Riviere-Cazaux, C., Shen, Y., and Zhou, M. (2021) Insight into the roles of CCR5 in learning and memory in normal and disordered states. *Brain Behav. Immun.* **92**, 1–9

9. Martin-Blondel, G., Brassat, D., Bauer, J., Lassmann, H., and Liblau, R.S. (2016) CCR5 blockade for neuroinflammation and CADIRIS Study Team (2014) Effect of the CCR5 antagonist maraviroc on the occurrence of immune efficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. *J. Virol.* **80**, 7602–7609

10. Cui, L.-Y., Chu, S.-F., and Chen, N.-H. (2020) The role of chemokines and chemokine receptors in multiple sclerosis. *Int. Immunopharmacol.* **83**, 106314

11. Aldinucci, D., and Casagrande, N. (2018) Inhibition of the CCL5/CCR5 axis against the progression of gastric cancer. *Int. J. Mol. Sci.* **19**, 1477

12. Jiao, X., Nawab, O., Patel, T., Kossenko, A.V., Halama, N., Jaeger, D., and Pestell, R.G. (2019) Recent advances targeting CCR5 for cancer and its role in immuno-oncology. *Cancer Res.* **79**, 4801–4807

13. Aldinucci, D., and Colombatti, A. (2014) The inflammatory chemokine CCL5 and cancer progression. *Mediat. Inflamm.* **2014**, 1–12

14. Prahalad, S. (2006) Negative association between the chemokine receptor CCR5Δ32 and rheumatoid arthritis: a meta-analysis. *Genes Immun.* **7**, 264–268

15. Szalai, C., Duba, J., Prohászka, Z., Kalina, Á., Szabó, T., Nagy, B., Horváth, L., and Császár, A. (2001) Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp (a) and MCP-1 of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). *Atherosclerosis* **158**, 233–239

16. Liu, R., Paxton, W.A., Choe, S., Ceradini, D., Martin, S.R., Horuk, R., Mac Donald, M.E., Stuhlman, H., Koup, R.A., and Landau, N.R. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. *Cell* **86**, 367–377

17. Rustemoglu, A., Ekinci, D., Nursal, A.F., Barut, S., Duygu, F., and Gönal, Ö. (2017) The possible role of CCR5Δ32 mutation in Crimean-Congo hemorrhagic fever infection. *J. Med. Virol.* **89**, 1714–1719

18. Rahbar, R., Murooka, T.T., Hinek, A.A., Galligan, C.L., Sassano, A., Yu, C., Srivastava, K., Platianis, L.C., and Fish, E.N. (2006) Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication. *J. Virol.* **80**, 7245–7259

19. Rahbar, R., Murooka, T.T., and Fish, E.N. (2009) Role for CCR5 in dissemination of vaccinia virus in vivo. *J. Virol.* **83**, 2226–2236

20. Alonzo, F., III, Kozhaya, L., Rawlings, S.A., Reyes-Robles, T., DuMont, A.L., Myszka, D.G., Landau, N.R., Unutmaz, D., and Torres, V.J. (2013) CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. *Nature* **493**, 51–55

21. Okamoto, M., Toyama, M., and Baba, M. (2020) The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. *Antivir. Res.* **182**, 104902

22. Agresti, N., Lalezari, J.P., Amodeo, P.P., Mody, K., Mosher, S.F., Seethamaraju, H., Kelly, S.A.; Pourhassan, N.Z.; Suduth, C.D., Bovinet, C., ElSharkawi, A.E., Patterson, B.K., Stephen, R., Sacha, J.B., Wu, H.L., Gross, S.A., and Dhody, K. (2021) Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: case series of four critically ill patients treated with leronlimab. *J. Transl. Autoimmun.* **4**, 100083

23. Costela-Ruiz, V.J., Illescas-Montes, R., Puerta-Puerta, J.M., Ruiz, C., and Melguizo-Rodríguez, L. (2020) SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. *Cytokine Growth Factor Rev.* **54**, 62–75

24. Mack, M., Luckow, B., Nelson, P.J., Cihak, J., Simmons, G., Clapham, P.R., Signoret, N., Marsh, M., Stangassinger, M., Borlat, F., Wells, T.N.C., Schlöndorff, D., and Proudfoot, A.E.I. (1998) Aminoxypropionate-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. *J. Exp. Med.* **187**, 1215–1224

25. Kawamura, T., Bruce, S.E., Abrahá, M., Hartley, O., Offord, R.E., Arts, E.J., Zimmerman, P.A., and Blauvelt, A. (2004) PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. *J. Virol.* **78**, 7602–7609

26. Redwine, L.S., Pert, C.B., Rone, J.D., Nixon, R., Vance, M., Sandler, B., Lumpkin, M.D., Dieter, D.J., and Ruff, M.R. (1999) Peptide T blocks GP120/CCR5 chemokine receptor-mediated chemotaxis. *Clin. Immunol.* **93**, 124–131

27. Ray, N. (2008) Maraviroc in the treatment of HIV infection. *Drug Des. Dev. Ther.* **2**, 151

28. Sierra-Madero, J.G., Ellenberg, S.S., Rassoul, M.S., Tierney, A., Belaunzarán-Zamudio, P.F., López-Martínez, A., Piñeirúa-Menéndez, A., Montaner, L.J., Azconi, L., Benítez, C.R., Sereti, I., Andrade-Villanueva, J., Mosqueda-Gómez, J.L., Rodriguez, B., Sanne, I., Lederman, M.M., and CADIRIS Study Team (2014) Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. *The Lancet HIV* **1**, e60–e67

29. Ochoa-Callejero, L., Pérez-Martínez, L., Rubio-Mediavilla, S., Oto, J.A., Martínez, A., and Blanco, J.R. (2013) Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. *PLoS One* **8**, e53992

30. Halvorsen, E., Hamilton, M., Young, A., Wadsworth, B., LePard, N., Lee, H., Firmino, N., Collier, J., and Bennworth, K. (2016) Maraviroc decreases CCL8-mediated migration of CCR5+ regulatory T cells and reduces metastatic tumor growth in the lungs. *Oncoimmunology* **5**, e1150398

31. Latinovic, O., Kuruppu, J., Davis, C., Le, N., and Here dia, A. (2009) Pharmacotherapy of HIV-1 infection: focus on CCR5 antagonist maraviroc. *Clin. Med. Ther.* **1**, CMT.S2365

32. Gutierrez, M.D.M., Mur, I., Mateo, M.G., Vidal, F., and Domingo, P. (2021) Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). *Expert. Opin. Pharmacother.* **22**, 1127–1141

33. Friedman, S., Sanyal, A., Goodman, Z., Lefebvre, E., Gottwald, M., Fischer, L., and Ratziu, V. (2016) Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis:
CENTAUR phase 2b study design. *Contemp. Clin. Trials* **47**, 356–365.

34. Anstee, Q.M., Neuschwander-Tetri, B.A., Wong, W.V.-S., Abdelmalek, M.F., Younossi, Z.M., Yuan, J., Pecoraro, M.L., SeyediKazemi, S., Fischer, L., Bedossa, P., Goodman, Z., Alkhouri, N., Tacke, F., and Sanyal, A. (2020) Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA phase 3 study design. *Contemp. Clin. Trials* **89**, 105922.

35. Baba, M., Takashima, K., Miyake, H., Kanzaki, N., Teshima, K., Wang, X., Shiraiishi, M., and Iizawa, Y. (2005) TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. *Antimicrob. Agents Chemother.* **49**, 4584–4591.

36. Berlin, C.-U. (2020) Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients.

37. Qi, B., Fang, Q., Liu, S., Hou, W., Li, J., Huang, Y., and Shi, J. (2020) Advances of CCR5 antagonists: from small molecules to macromolecules. *Eur. J. Med. Chem.* **208**, 112819.

38. Olson, W.C., Rabut, G.E., Nagashima, K.A., Tran, D.N., Anselma, D.J., Monard, S.P., Segal, J.P., Thompson, D.A., Kajumo, F., Guo, Y., Moore, J.P., Maddon, P.J., and Dragic, T. (1999) Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. *J. Virol.* **73**, 4145–4155.

39. Jacobson, J.M., Lalezari, J.P., Thompson, M.A., Fichtenbaum, C.J., Saag, M.S., Zingman, B.S., D’Ambrosio, P., Stambler, N., Rothstein, Y., Marozsan, A.J., Maddon, P.J., Morris, S.A., and Olson, W.C. (2010) Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. *Antimicrob. Agents Chemother.* **54**, 4137–4142.

40. Cristofanilli, M., Dolezal, M., Lalezari, J., Rui, H., Patterson, B., Tang, C.-M., Adams, D., Zhang, Q., Kazempour, K., and Pourhassan, N. (2020) Abstract CT233: phase Ib/II study of lenzilimumab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients. *AACR*.

41. Skendelas, J., Phan, D., Caputo, V., Stryker, K., Ahmed, S., Philippsborn, P., Thalappillil, J., Scheinin, S., and Seethamraju, H. (2021) Novel CCR5 antagonist for the treatment of mild-moderate COVID-19 infection after lung transplant. *J. Heart Lung Transplant.* **40**, S315.

42. Starich, B.R., Hahn, B.H., Shaw, G.M., McNeely, P.D., Modrow, S., Wolf, H., Parks, E.S., Parks, W.P., Josephs, S.F., Gallo, R.C., and Wong-Staal, F. (1986) Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LA V , the retrovirus of AIDS. *Cell* **45**, 637–648.

43. Leonard, C.K., Spellman, M.W., Riddle, L., Harris, R.J., Thomas, J.N., and Gregory, T. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. *J. Biol. Chem.* **265**, 10373–10382.

44. Xiang, S.-H., Finzi, A., Pacheco, B., Alexander, K., Yuan, W., Rizzuto, C., Huang, C.-C., Kwong, P.D., and Sodroski, J. (2010) A V3 loop-dependent gp120 particle disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimmer. *J. Virol.* **84**, 3147–3161.

45. Cardozo, T., Kimura, T., Philpott, S., Weiser, B., Burger, H., and Zolla-Pazner, S. (2007) Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. *AIDS Res. Hum. Retrovir.* **23**, 415–426.

46. Foda, M., Harada, S., and Maeda, Y. (2001) Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity. *Microbiol. Immunol.* **45**, 521–530.

47. Hartley, O., Klasse, P.J., Sattentau, Q.J., and Moore, J.P. (2005) V3: HIV’s switch-hitter. *AIDS Res. Virol.* **21**, 171–189.

48. Hongjiaisee, S., Braibant, M., Barin, F., Ngo-Giang-Huong, N., Sirirungsi, W., and Samleerat, T. (2017) Effect of amino acid substitutions within the V3 region of HIV-1 CRF01_AE on interaction with CCR5-coreceptor. *AIDS Res. Hum. Retrovir.* **33**, 946–951.

49. Huang, C.-C., Tang, M., Zhang, M.-Y., Majeed, S., Montanana, E., Stanfield, R.L., Dimitrov, D.S., Korber, B., Sodroski, J., Wilson, I.A., Wyatt, R., and Kwong, P.D. (2005) Structure of a V3-containing HIV-1 gp120 core. *Science* **310**, 1025–1028.

50. Jiang, X., Burke, V., Totrov, M., Williams, C., Cardozo, T., Gorny, M.K., Zolla-Pazner, S., and Kong, X.-P. (2010) Conserved structural elements in the V3 crown of HIV-1 gp120. *Nat. Struct. Mol. Biol.* **17**, 955–961.

51. Moore, J.P., and Nara, P.L. (1991) The role of the V3 loop of gp120 in HIV infection. *AIDS* **5**, 21–34.

52. O’Brien, W.A., Koyanagi, Y., Namazie, A., Zhao, J.-Q., Diagne, A., Zack, J.A., and Chen, I.S. (1990) HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. *Nature* **348**, 69–73.

53. Shioda, T., Levy, J.A., and Cheng-Mayer, C. (1991) Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120. *Nature* **349**, 167–169.

54. Trujillo, J.R., Wang, W.-K., Lee, T.-H., and Essex, M. (1996) Identification of the envelope V3 loop as a determinant of a CD4-negative neuronal cell tropism for HIV-1. *Virology* **217**, 613–617.

55. Westervelt, P., Trowbridge, D., Epstein, L., Blumberg, B., Li, Y., Hahn, B., Shaw, G., Price, R., and Ratner, L. (1992) Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. *J. Virol.* **66**, 2577–2582.

56. LaRosa, G.J., Davide, P., Weinhold, K., Waterbury, J.A., Profy, A.T., Lewis, J.A., Langlois, A.J., Dreesman, G.R., Boswell, R.N., Shadduck, P., Holley, L.H., Karplus, M., Bolognesi, D.P., Matthews, T.J., Emini, E.A., and Putney, S.D. (1990) Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. *Science* **249**, 932–935.

57. LaRosa, G.J., Weinhold, K., Profy, A.T., Langlois, A.J., Dreesman, G.R., Boswell, R.N., Shadduck, P., Bolognesi, D.P., Matthews, T.J., Emini, E.A., and Putney, S.D. (1991) Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications. *Science* **253**, 1146–1147.

58. Javaherian, K., Langlois, A.J., McDanel, C., Ross, K.L., Eckler, L.I., Jellis, C.L., Profy, A.T., Rusche, J.R., Bolognesi, D.P., and Putney, S.D. (1989) Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. *Proc. Natl. Acad. Sci. U. S. A.* **86**, 6768–6772.

59. Cormier, E.G., and Dragic, T. (1990) HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. *Nature* **348**, 69–73.

60. de Victoria, A.L., Tamamis, P., Kieslich, C.A., and Morikis, D. (2012) Insights into the structure, correlated motions, and
electrostatic properties of two HIV-1 gp120 V3 loops. *PLoS One* **7**, e49925

63. Vranken, W.F., Budesinsky, M., Fant, F., Boulez, K., and Borremans, F.A. (1995) The complete consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution. *Fed. Eur. Biochem. Soc. Lett.* **374**, 117–121

64. Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G.W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., Zhang, W., Xie, X., Yang, H., Jiang, H., Cherezov, V., Liu, H., Stevens, R.C., Zhao, Q., and Wu, B. (2013) Structure of the CCR5 chemokine receptor–HIV entry inhibitor maravirex complex. *Science* **341**, 1387–1390

65. Pront, S., Päll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M.R., Smith, J.C., Kasson, P.M., van der Spoel, D., Hess, B., and Lindahl, E. (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. *Bioinformatics* **29**, 845–854

66. Kumari, R., Kumar, R., Consortium, O.S.D.D., and Lynn, A. (2014) g_mmpbsa white medium square a GROMACS tool for high-throughput MM-PBSA calculations. *J. Chem. Inf. Model.* **54**, 1951–1962

67. Pierce, B.G., Hourai, Y., and Weng, Z. (2011) Accelerating protein docking in ZDOCK using an advanced 3D convolution library. *PLoS One* **6**, e24657

68. Ahmed, M., Basheer, H.A., Ayuso, J.M., Ahmet, D., Mazzini, M., Patel, R., Shnyder, S.D., Vinader, V., and Afarinkia, K. (2017) Agarose spot as a comparative method for in situ analysis of simultaneous chemotactic responses to multiple chemokines. *Sci. Rep.* **7**, 1–11

69. Liebick, M., Schläger, C., and Oppermann, M. (2016) Analysis of chemokine receptor trafficking by site-specific biotinylation. *PLoS One* **11**, e0157502

70. Li, N., Hill, K.S., and Elferink, L.A. (2008) Analysis of simultaneous chemotactic responses to multiple chemokines. *PLoS One* **3**, e0157502

71. Pierree, T., Hourai, Y., and Weng, Z. (2011) Amino-terminal substitutions in the CCR5 coreceptor domain are involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. *J. Mol. Recognit.* **28**, 581–604

72. Su, J., Palm, A., Wu, Y., Sandin, S., Hoglund, S., and Vahlne, A. (2000) Deletion of the GPG motif in the HIV type 1 V3 loop does not abrogate infection in all cells. *AIDS Res. Hum. Retrovir.* **16**, 37–48

73. Dragic, T., Trkola, A., Lin, S.W., Nagashima, K.A., Farzan, M., Choe, H., Vaca, L., Martin, K., Sun, Y., Desjardins, E., Ruffing, N., Wu, L., Wyatt, R., Gerard, N., Gerard, C., and Sodroski, J. (1998) A hypervariable region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. *J. Virol.* **72**, 1160–1164

74. Wang, W.-K., Dudek, T., Essex, M., and Lee, T.-H. (1999) Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. *Proc. Natl. Acad. Sci. U. S. A.* **96**, 4558–4562

75. Cornier, E.G., Tran, D.N., Yukhayeva, L., Olson, W.C., and Dragic, T. (2001) Mapping the determinants of the CCR5 amino-terminal sulfopetide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. *Journal of virology* **75**, 5541–5549

76. Yuriev, E., Holien, J., and Ramsland, P.A. (2015) Improvements, trends, and new ideas in molecular docking: 2012–2013 in review. *J. Mol. Recognit.* **28**, 581–604

77. 162

78. 163

79. 164
92. Boppana, S., and Goepfert, P. (2018) Understanding the CD8 T-cell response in natural HIV control. F1000Research. 7.

93. Claireaux, M., Robinot, R., Kervevan, J., Patgaonkar, M., Staropoli, I., Brelot, A., Nouel, A., Gellenoncourt, S., Tang, X., Héry, M., Volant, S., Perthame, E., Avetand-Fenoël, V., Buchrieser, J., Cokelaer, T., Bouchier, C., Ma, L., Boufassa, F., Hendou, S., Libri, V., Hasan, M., Zucman, D., de Truchis, P., Schwartz, O., Lambotte, O., and Chakrabarti, L.A. (2022) Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry. Nat. Commun. 13, 1–19.

94. Potard, V., Reyne, J., Ferry, T., Aubin, C., Finkielstien, L., Yazdanpanah, Y., Costagliola, D., and CO4, F.A. (2015) Durability and effectiveness of Maraviroc-containing regimens in HIV-1-infected individuals with virological failure in routine clinical practice. PLoS One 10, e0144746.

95. López-Huertas, M.R., Gutiérrez, C., Madrid-Elena, N., Hernández-Novoa, B., Olalla-Sierra, J., Plana, M., Delgado, R., Rubio, R., Muñoz-Fernández, M.A., and Moreno, S. (2020) Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound. Sci. Rep. 10, 1–13.

96. Polianova, M.T., Ruscetti, F.W., Pert, C.B., and Ruff, M.R. (2005) Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antivir. Res. 67, 83–92.

97. Polianova, M.T., Ruscetti, F.W., Pert, C.B., Tractenberg, R.E., Leoung, G., Sarr, S., and Ruff, M.R. (2003) Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA). Peptides 24, 1093–1098.

98. Venanzi Rullo, E., Cecarelli, M., Cordorelli, F., Faccioli, A., Visalli, G., D’Aleo, F., Paolucci, I., Cacopardo, B., Pinzone, M.R., and Di Rosa, M. (2019) Investigational drugs in HIV: pros and cons of entry and fusion inhibitors. Mol. Med. Rep. 19, 1987–1995.

99. Nishihara, Y., Igarashi, T., Donau, O.K., Buckler-White, A., Buckler, C., Lafont, B.A., Goeckner, R.M., Goldstein, S., Hirsch, V.M., and Martin, M.A. (2004) Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. PNAS 101, 12324–12329.

100. Li, Q., Duan, L., Estes, J.D., Ma, Z.-M., Rourke, T., Wang, Y., Reilly, C., Carlis, J., Miller, C.J., and Haase, A.T. (2005) Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434, 1148–1152.

101. Mattapallil, J.J., Douek, D.C., Hill, B., Nishimura, Y., Martin, M., and Roederer, M. (2005) Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434, 1093–1097.

102. Shi, S., Nguyen, P.K., Cabral, H.J., Diez-Barroso, D., Derry, P.J., Kanahara, S.M., and Kumar, V.A. (2016) Development of peptide inhibitors of HIV transmission. Bioact. Mater. 1, 109–121.

103. Belvisi, L., D’Andrea, L.D., and Jiménez, M.A. (2021) Peptides targeting protein-protein interactions: methods and applications. Front. Mol. Biosci. 8.

104. Gaertner, H., Cerini, F., Escola, J.-M., Kuenzi, G., Melotti, A., Offord, R., Rossitso-Borlat, I., Nedellec, R., Salkowitz, J., Gorochov, G., Mosier, D., and Hartley, O. (2008) Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. U. S. A. 105, 17706–17711.

105. Nedellec, R., Coetzer, M., Lederman, M.M., Offord, R.E., Hartley, O., and Mosier, D.E. (2011) Resistance to the CCR5 inhibitor SP12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use. PLoS One 6, e22020.

106. Tamamis, P., and Floudas, C.A. (2014) Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop. PLoS One 9, e95767.

107. Catasti, P., Fontenot, J.D., Bradbury, E.M., and Gupta, G. (1995) Local and global structural properties of the HIV-MN V3 loop. J. Biol. Chem. 270, 2224–2232.

108. Suphaphiphat, P., Essex, M., and Lee, T.-H. (2007) Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor. Virology 360, 182–190.

109. Sakaida, H., Hori, T., Yonezawa, A., Sato, A., Isaka, Y., Yoshie, O., Hattori, T., and Uchiyama, T. (1998) T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR4- and inhibit T-tropic HIV-1 infection. J. Virol. 72, 9763–9770.

110. Salo-Ahen, O.M., Alanfo, I., Bhadane, R., Bonvin, A.M., Honorarto, R.V., Hossain, S., Juffer, A.H., Kabe-dev, A., Lahtela-Kakkonen, M., Larsen, A.S., Lescriner, E., Marimuthu, P., Mizra, M.U., Mustafa, G., Nunes-Alves, A., Pantsar, T., Saadabadi, A., Singaravelu, K., and Vanmeert, M. (2021) Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes 9, 71.

111. Samson, M., LaRosa, G., Libert, F., Paindavoine, P., Deheux, M., Vassart, G., and Parmentier, M. (1997) The second extracellular loop of CCR5 is the major determinant of ligand specificity. J. Biol. Chem. 272, 24934–24941.

112. Blanpain, C., Doran, B.J., Vakili, J., Rucker, J., Govaerts, C., Baik, S.S., Lorthioir, O., Migote, I., Libert, F., Baleux, F., Vassart, G., Doms, R.W., and Parmentier, M. (1999) Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J. Biol. Chem. 274, 34719–34727.

113. Nishikawa, M., Takashima, K., Nishi, T., Furuta, R.A., Kanazaki, N., Yamamoto, Y., and Fujisawa, J.-I. (2005) Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob. Agents Chemother. 49, 4708–4715.

114. Dragic, T., Trkola, A., Thompson, D.A., Cormier, E.G., Kajumo, F., Maxwell, E., Lin, S.W., Ying, W., Smith, S.O., Sakmar, T.P., and Moore, J.P. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A. 97, 5639–5644.

115. Tsamis, F., Gavrilov, S., Kajumo, F., Seibt, C., Kuhmann, S., Ketas, T., Trkola, A., Palani, A., Clader, J.W., Tagat, J.R., McCombie, S., Baroudy, B., Moore, J.P., Sakmar, T.P., and Dragic, T. (2003) Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77, 5201–5208.

116. Shai, M.M., Peng, H., Lu, J., Rits-Volloch, S., Xu, C., Liao, M., and Chen, B. (2019) Structural basis of coreceptor recognition by HIV-1 envelope spike. Nature 565, 318–323.

117. Tamamis, P., and Floudas, C.A. (2015) Elucidating a key anti-HIV and cancer-associated axis: the structure of CCL5 (Rantes) in complex with CCR5. Sci. Rep. 4, 1–9.

118. Kondru, R., Zhang, J., Ji, C., Mirzadegan, T., Rotstein, D., Sankurati, S., and Dossosgi, M. (2008) Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73, 789–800.

119. Tan, Y., Tong, P., Wang, J., Zhao, L., Li, J., Yu, Y., Chen, Y.-H., and Wang, J. (2017) The membrane-proximal region of C-C chemokine receptor type 5 participates in the infection of HIV-1. Front. Immunol. 8, 478.
120. Recum, H.A.V., and Pokorski, J.K. (2013) Peptide and protein-based inhibitors of HIV-1 co-receptors. *Exp. Biol. Med. (Maywood)* **238**, 442–449
121. Olson, T.S., and Ley, K. (2002) Chemokines and chemokine receptors in leukocyte trafficking. *Am. J. Phys. Regul. Integr. Comp. Phys.* **283**, R7–R28
122. Signoret, N., Pelchen-Matthews, A., Mack, M., Proudfoot, A.E., and Marsh, M. (2000) Endocytosis and recycling of the HIV coreceptor CCR5. *J. Cell Biol* **151**, 1281–1294
123. Jin, T., Xu, X., and Hereld, D. (2008) Chemotaxis, chemokine receptors and human disease. *Cytokine* **44**, 1–8
124. Patterson, B.K., Seethamraju, H., Dhody, K., Corley, M.J., Kazempour, K., Lalezari, J., Pang, A.P., Sugai, C., Mahyari, E., Francisco, E.B., Pise, A., Rodrigues, H., Wu, H.L., Webb, G.M., Park, B.S., Kelly, S., Pourhassan, N., Lelic, A., Kdouh, L., Herrera, M., Hall, E., Bimber, B.N., Plassmeyer, M., Gupta, R., Alpan, O., O’Halloran, J.A., Mudd, P.A., Akalin, E., Ndlovu, L.C., and Sacha, J.B. (2021) CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. *Int. J. Infect. Dis.* **103**, 25–32